AbbVie Stock Buy or Sell? ABBV Stocks Forecast

Market Capitalization: 314 151 338 000 $
EBITDA: 26 254 332 000 $
Price to Earnings: 65.42
Quarterly Earnings Growth YOY: -0.668
Quarterly Revenue Growth YOY: -0.054
Trailing PE: 65.42
Forward PE: 15.7
Shares Outstanding: 1765540000






Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Getting A Kredittkort Norge Approval Isn’t Difficult

February 8, 2024 Getting A Kredittkort Norge Approval Isn’t Difficult

If you meet the conditions, you can open an account for checking in Norway. However, it will be much easier and more convenient…
How to Understand Social Security: 6 Legal & Financial Tips

January 25, 2024 How to Understand Social Security: 6 Legal & Financial Tips

Understanding social security can seem overwhelming, but it’s an important part of financial planning, particularly for retirement. The following 6 legal and financial…
Finding Energy Plans with Billig Strøm Rates

January 10, 2024 Finding Energy Plans with Billig Strøm Rates

It can be overwhelming to decide on the best plan when in a state where electricity is deregulated. The number of providers is…

AbbVie Stock Buy or Sell? ABBV Stocks Analytic Forecasts

Updated on February 27, 2024 (10:19)

AbbVie Inc. (ABBV prediction charts) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the ABBV stock market. Experts share their opinions on what to expect from the AbbVie Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell AbbVie stocks.

AbbVie Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy ABBV Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Kody’s Dividends and is titled

“AbbVie Q4: Now Isn’t The Time To Buy My Largest Big Pharma Holding”

is published on February 7 (2024) and has 0 likes. The review predicts Neutral market trend.

It summarize the following theses:

  • The total returns of AbbVie’s shares have tripled that of the S&P 500 since I last covered it in November.
  • The big pharma company’s fourth-quarter financial results were mixed.
  • AbbVie possesses an A- credit rating from S&P on a stable outlook.
  • Shares could be 9% overvalued at the current share price.
  • I am awaiting a pullback to $155 and below before adding more to my position in AbbVie.

The author starts his analytic review with the following:

Over near-term to medium-term time frames, financial markets often swing too far in either the direction of greed or fear. That is, share price movements can be exaggerated beyond what is justified by fundamentals.

The opinion of the author can be considered quite authoritative.
The number of 8218 followers confirms this.
Kody’s Dividends is the contributor of experts community
since 2018 and has 356 works published.


One more noteworthy article is written by Stone Fox Capital under the title

“AbbVie: Game Changer”

on February 6 (2024) and has 0 likes. The expert reflects Strong Bullish trend of the market.

Нis theses make you think about whether to add ABBV stocks to your investment portfolio or not, and helps to work out your own AbbVie stock selling strategies:

  • AbbVie Inc. is showing signs of growth beyond the loss of exclusivity for Humira, with strong 2024 guidance.
  • Sales of Skyrizi and Rinvoq are replacing lost Humira sales, with projected sales more than doubling through 2027.
  • AbbVie’s acquisitions of ImmunoGen and Cerevel Therapeutics are expected to further boost sales, though add $18.7 billion to debt.
  • The stock is relatively cheap, trading at 14x ’25 EPS targets.

Stone Fox Capital starts analysis with such words:

Even before a couple of major acquisitions close and impact results, AbbVie Inc. (NYSE:ABBV) is showing solid signs of growing beyond the Humira loss of exclusivity. The stock has already soared to yearly highs on the back of solid 2024 guidance. My investment thesis remains Bullish on the biopharma moving back towards growth mode this year.

This author is very popular among the auditory. He has 46088 followers

Stone Fox Capital is the contributor of experts community since 2008. Has published at least 4948 articles.


Another analysis presented by Tradevestor came out on February 6 (2024). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for ABBV stocks. It sounds like

“AbbVie Q4 Review: Stock Remains A Buy, Encouraged By Skyrizi And Rinvoq”

Article has got 0 likes at the moment and forecasting Bullish trend of the market.

Summarizing the information presented in the review concerning the AbbVie Inc., the expert says the following:

  • AbbVie Inc.’s Q4 revenue beat expectations, a positive sign considering the expiration of Humira exclusivity in 2023.
  • Skyrizi and Rinvoq contributed $3.7 billion to Q4 revenue, showing strong growth that prompted the company to guide up its 2027 sales projections by $6 billion.
  • AbbVie’s stock is technically strong and has room for further upside before becoming overbought.

And here, what comes first:

AbbVie Inc. (NYSE:ABBV) recently reported its Q4 results as Seeking Alpha has covered here. The stock went up less than 1% after the earnings but is up nearly 9% YTD. 2023 was expected to be a challenging year for the company given the Humira patent expiration. How did AbbVie perform in Q4 and 2023 in general? Let’s find out below.

The opinion of the author can be considered quite authoritative.
The number of 7654 followers confirms this.
Tradevestor is the contributor of experts community since 2012. Has already 640 analytic reviews published.


The Share Price of AbbVie Inc. (ABBV) for now

What analysts predict: $179.25
52-week high/low: $178.92 / $127.03

50/200 Day Moving Average: $162.13 / $148.4

The average stock price over the previous 50/200 days. For AbbVie stocks, the 50-day moving average is the resistance level for now. For ABBV stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for ABBV stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness

Buy or Sell TMO shares? Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness
February 6, 2024
Drug manufacturers are facing a massive patent cliff, with over $200 billion in annual revenue at risk through 2030, meaning innovation is critical to prop up sales, and today's company focuses on that.

Revisiting Zynerba Pharmaceuticals

Buy or Sell ZYNE shares? Revisiting Zynerba Pharmaceuticals
November 11, 2021
Today, we revisit a small developmental firm called Zynerba Pharmaceuticals.

Danaher: Better Positioned For The Future

Buy or Sell DHR shares? Danaher: Better Positioned For The Future
February 3, 2024
Danaher's annual results show a decrease in sales and EBIT due to the boost in sales of the COVID-19 pandemic.